登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C20H32N5O8P
化学文摘社编号:
分子量:
501.47
NACRES:
NA.76
PubChem Substance ID:
UNSPSC Code:
51102829
MDL number:
InChI key
WOZSCQDILHKSGG-UHFFFAOYSA-N
SMILES string
CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C
InChI
1S/C20H32N5O8P/c1-19(2,3)17(26)30-11-32-34(28,33-12-31-18(27)20(4,5)6)13-29-8-7-25-10-24-14-15(21)22-9-23-16(14)25/h9-10H,7-8,11-13H2,1-6H3,(H2,21,22,23)
biological source
synthetic
assay
≥98% (HPLC)
form
powder
solubility
ethanol: 50 mg/mL
antibiotic activity spectrum
viruses
mode of action
enzyme | inhibits
storage temp.
−20°C
Quality Level
Biochem/physiol Actions
Adefovir is an antiviral acyclic nucleoside phosphonate (ANP) analog that works by blocking reverse transcriptase. It is an inhibitor of duck hepatitis B virus (DHBV) replication that inhibits covalently closed circular DNA (CCC DNA) amplification. Cytotxicity is induced by Human Renal Organic Anion Transporter 1 (hOAT1). Adefovir is an Inhibitor of edema factor (EF)-induced cAMP accumulation and changes in cytokine production in mouse primary macrophages .
Other Notes
Keep container tightly closed in a dry and well-ventilated place.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Julien Delmas et al.
Antimicrobial agents and chemotherapy, 46(2), 425-433 (2002-01-18)
The elimination of viral covalently closed circular DNA (CCC DNA) from the nucleus of infected hepatocytes is an obstacle to achieving sustained viral clearance during antiviral therapy of chronic hepatitis B virus (HBV) infection. The aim of our study was
A Takeda et al.
Journal of viral hepatitis, 14(2), 75-88 (2007-01-25)
Standard treatments for chronic hepatitis B (CHB) include interferon-alpha (IFN-alpha) and lamivudine (LAM), but these are associated with adverse effects and viral resistance, respectively. The aim of this systematic review and economic evaluation was to assess the clinical effectiveness and
F Stelma et al.
Journal of viral hepatitis, 24(12), 1107-1113 (2017-06-21)
Combining peginterferon-alfa-2a (pegIFN) with a nucleotide analogue can result in higher rates of HBsAg loss than either therapy given alone. Here, we investigated the durability of the response to combination therapy in chronic hepatitis B (CHB) patients after 5 years of
Baek Gyu Jun et al.
PloS one, 13(7), e0201316-e0201316 (2018-07-31)
Convincing data that support routine use of preventive therapy against hepatitis B virus (HBV) reactivation in radiotherapy (RT) for hepatocellular carcinoma (HCC) are lacking. The aim of this study was to investigate the incidence, clinical significance, and risk factors of
Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection.
Yuequan Shen, Natalia L. Zhukovskaya, et. Al
Proceedings of the National Academy of Sciences of the USA, 101, 3234-3247 (2004)
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持